Oct 19, 2026 02:21PM
Oct 19, 2026 02:18PM
Sep 22, 2026 07:36AM
Sep 21, 2026 04:15PM
Aug 25, 2026 07:37AM
Jul 15, 2026 08:45AM
May 12, 2026 04:15PM Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
Apr 28, 2026 07:12PM
Mar 3, 2026 04:15PM
Feb 25, 2026 07:19AM
Feb 25, 2026 07:18AM
Dec 19, 2025 09:06AM
Dec 15, 2025 07:01AM
Dec 15, 2025 07:00AM Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Nov 4, 2025 04:15PM
Oct 1, 2025 01:20PM
Oct 1, 2025 01:13PM
Sep 30, 2025 06:48AM
Sep 29, 2025 04:07PM
Sep 29, 2025 04:05PM
Aug 6, 2025 04:15PM Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
May 5, 2025 04:15PM
Feb 28, 2025 12:26PM
Feb 27, 2025 04:15PM
Feb 3, 2025 07:30AM
Feb 3, 2025 07:30AM
Jan 6, 2025 10:35AM
Aug 5, 2024 04:15PM Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
May 9, 2024 04:12PM
May 9, 2024 04:10PM
May 9, 2024 04:05PM
Oct 9, 2023 08:02AM
Oct 9, 2023 08:00AM
Aug 7, 2023 04:15PM
Jul 31, 2023 01:36PM Anaptysbio (ANAB) and GSK’s JEMPERLI plus Chemo Approved in the US for dMMR/MSI-H Cancer
Jul 31, 2023 01:34PM
May 11, 2023 04:15PM
May 2, 2023 09:16AM
May 2, 2023 09:15AM
May 2, 2023 09:15AM
Mar 28, 2023 05:49AM
Mar 27, 2023 06:50PM AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survi
Mar 27, 2023 06:50PM
Mar 1, 2023 04:05PM
Mar 1, 2023 04:05PM
Jan 5, 2023 04:08PM
Jan 5, 2023 04:05PM
Jan 5, 2023 04:05PM
Dec 2, 2022 09:01AM Anaptysbio (ANAB), GSK (GSK) -partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
Dec 2, 2022 09:00AM

335,206 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All